ReviewEuropean respiratory review : an official journal of the European Respiratory Society2018
Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases.
Review in European respiratory review : an official journal of the European Respiratory Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Care programs and their components for patients with idiopathic pulmonary fibrosis: a systematic review.Respiratory research · 2021Pooled it
- Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.Advances in therapy · 2021Pooled it
- Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.Journal of managed care & specialty pharmacy · 2024Article
- Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.BMC pulmonary medicine · 2023Article
- Burden of illness in progressive fibrosing interstitial lung disease.Journal of managed care & specialty pharmacy · 2022Article
- Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.Annals of the American Thoracic Society · 2022Article
- C/EBP homologous protein promotes Sonic Hedgehog secretion from type II alveolar epithelial cells and activates Hedgehog signaling pathway of fibroblast in pulmonary fibrosis.Respiratory research · 2022Article
- Prognostic Predictive Characteristics in Patients With Fibrosing Interstitial Lung Disease: A Retrospective Cohort Study.Frontiers in pharmacology · 2022Article
- Cost drivers in the pharmacological treatment of interstitial lung disease.Respiratory research · 2021Observational
- Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2019Article
- Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are over 200 interstitial lung diseases (ILDs). In addition to patients with idiopathic pulmonary fibrosis (IPF), a percentage of patients with other ILDs also develop progressive fibrosis of the lung during their disease course. Patients with progressive-fibrosing ILDs may show limited response to immunomodulatory therapy, worsening symptoms and lung function and, ultimately, early mortality. There are few data for ILDs that may present a progressive fibrosing phenotype specifically, but we believe the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF. This review discusses the burden of ILDs that may present a progressive fibrosing phenotype and the factors impacting healthcare utilisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.